Curacyte AG, of Munich, Germany, appointed John Maraganore to its supervisory board.
Cypress Bioscience Inc., of San Diego, appointed Martin Keller and Sheldon Drobny to its board. Keller also will join the company¿s psychopharmacology advisory board. Separately, it appointed John Bonfiglio executive vice president and chief operating officer.
Dendreon Corp., of Seattle, added Deborah Elvins as associate general counsel and Mitchell Gold as vice president of business development.
diaDexus Inc., of Santa Clara, Calif., appointed Gregory Abbott and Jon Saxe to its board.
Dyax Corp., of Cambridge, Mass., named Jack Morgan senior vice president, corporate development and business operations; Pamela Hay senior vice president, corporate development and strategic opportunities; Albert Edge vice president of discovery and preclinical research; Ivana Maravic-Magovcevic vice president, intellectual property and chief patent counsel; and Joyce Samet vice president, legal affairs.
EntreMed Inc., of Rockville, Md., elected Jennie Hunter-Cevera to its board.
Forward Ventures, of San Diego, added Ivor Royston as a full-time managing member.
GenOdyssee, of Les Ulis, France, appointed Jean Maral vice president, senior director of preclinical and clinical affairs.
Genomica Corp., of Boulder, Colo., appointed Michael Savage to its board.
Genset SA, of Paris, appointed Robert Abarbanel chief information officer and chief technical officer.
GlycoDesign Inc., of Toronto, appointed Nelson Sims to its board.
Idun Pharmaceuticals Inc., of San Diego, appointed Charles Cashion executive vice president and chief financial officer.
ILEX Oncology Inc., of San Antonio, named Steven Weitman vice president, global cancer research, for its wholly owned subsidiary, ILEX Products Inc.